Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Ana Drozdowskyj, P. Bombaron et al.|The Lancet Oncology|2012

Cited by 5.5k